Tranzyme Pharma/Norgine's ghrelin agonist failure confirmed in second pivotal trial
This article was originally published in Scrip
Executive Summary
Tranzyme Pharma and Norgine's decision earlier this year to halt all NDA-related activities for the intravenous ghrelin agonist, ulimorelin, was backed up after the second of two pivotal Phase III trials investigating the drug in postoperative ileus failed.